Search Results - "MCGILL, Janet"

Safety of Sodium-Glucose Co-Transporter 2 Inhibitors by McGill, Janet B., Subramanian, Savitha

“…Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including…”
Get full text

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial by Beck, Roy W, Riddlesworth, Tonya, Ruedy, Katrina, Ahmann, Andrew, Bergenstal, Richard, Haller, Stacie, Kollman, Craig, Kruger, Davida, McGill, Janet B, Polonsky, William, Toschi, Elena, Wolpert, Howard, Price, David

“…IMPORTANCE: Previous clinical trials showing the benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly have…”
Get full text

Novel Agents in the Management of Diabetes and Risk of Worsening Diabetic Retinopathy by Rajagopal, Rithwick, McGill, Janet B

“…Novel therapies for diabetes have potent effects on glycemic control, obesity and cardiovascular risk reduction but some, including the popular drug…”
Get full text

Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial by Beck, Roy W, Riddlesworth, Tonya D, Ruedy, Katrina, Ahmann, Andrew, Haller, Stacie, Kruger, Davida, McGill, Janet B, Polonsky, William, Price, David, Aronoff, Stephen, Aronson, Ronnie, Toschi, Elena, Kollman, Craig, Bergenstal, Richard

“…Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2…”
Get full text

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases by Xie, Yan, Bowe, Benjamin, Gibson, Andrew K, McGill, Janet B, Maddukuri, Geetha, Yan, Yan, Al-Aly, Ziyad

“…To examine the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1), dipeptidyl…”
Get full text

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY by Garber, Alan J, Handelsman, Yehuda, Grunberger, George, Einhorn, Daniel, Abrahamson, Martin J, Barzilay, Joshua I, Blonde, Lawrence, Bush, Michael A, DeFronzo, Ralph A, Garber, Jeffrey R, Garvey, W Timothy, Hirsch, Irl B, Jellinger, Paul S, McGill, Janet B, Mechanick, Jeffrey I, Perreault, Leigh, Rosenblit, Paul D, Samson, Susan, Umpierrez, Guillermo E

Get more information

Clinical implications and guidelines for CKD in type 2 diabetes by Zhang, Rong M, Persson, Frederik, McGill, Janet B, Rossing, Peter

“…Chronic kidney disease (CKD) is a complication of type 2 diabetes (T2D) with high morbidity and mortality. The prevalence of CKD in T2D is increasing due to…”
Get full text

Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes by Bell, David S. H., McGill, Janet B., Jerkins, Terri

“…Patients with type 2 diabetes are at an increased risk of developing heart failure and chronic kidney disease. The presence of these co‐morbidities…”
Get full text

Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants by MILLER, Kellee M, BECK, Roy W, BERGENSTAL, Richard M, GOLAND, Robin S, HALLER, Michael J, MCGILL, Janet B, RODRIGUEZ, Henry, SIMMONS, Jill H, HIRSCH, Irl B

“…Despite substantial evidence of the benefit of frequent self-monitoring of blood glucose (SMBG) in type 1 diabetes, certain insurers limit the number of test…”
Get full text

Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association by Jerkins, Terri, McGill, Janet B., Bell, David S. H.

“…People with type 2 diabetes (T2DM) and those with prediabetes have an increased risk of heart failure (HF). Longer duration of T2DM correlates with a greater…”
Get full text

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes by Xie, Yan, Bowe, Benjamin, Gibson, Andrew K, McGill, Janet B, Maddukuri, Geetha, Al-Aly, Ziyad

“…In the treatment of type 2 diabetes, evidence of the comparative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas-the second…”
Get more information

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY by Garber, Alan J, Abrahamson, Martin J, Barzilay, Joshua I, Blonde, Lawrence, Bloomgarden, Zachary T, Bush, Michael A, Dagogo-Jack, Samuel, DeFronzo, Ralph A, Einhorn, Daniel, Fonseca, Vivian A, Garber, Jeffrey R, Garvey, W Timothy, Grunberger, George, Handelsman, Yehuda, Hirsch, Irl B, Jellinger, Paul S, McGill, Janet B, Mechanick, Jeffrey I, Rosenblit, Paul D, Umpierrez, Guillermo E

Get more information

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial by Pratley, Richard E, Kanapka, Lauren G, Rickels, Michael R, Ahmann, Andrew, Aleppo, Grazia, Beck, Roy, Bhargava, Anuj, Bode, Bruce W, Carlson, Anders, Chaytor, Naomi S, Fox, D Steven, Goland, Robin, Hirsch, Irl B, Kruger, Davida, Kudva, Yogish C, Levy, Carol, McGill, Janet B, Peters, Anne, Philipson, Louis, Philis-Tsimikas, Athena, Pop-Busui, Rodica, Shah, Viral N, Thompson, Michael, Vendrame, Francesco, Verdejo, Alandra, Weinstock, Ruth S, Young, Laura, Miller, Kellee M

“…Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1…”
Get full text

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY by Garber, Alan J, Abrahamson, Martin J, Barzilay, Joshua I, Blonde, Lawrence, Bloomgarden, Zachary T, Bush, Michael A, Dagogo-Jack, Samuel, DeFronzo, Ralph A, Einhorn, Daniel, Fonseca, Vivian A, Garber, Jeffrey R, Garvey, W Timothy, Grunberger, George, Handelsman, Yehuda, Hirsch, Irl B, Jellinger, Paul S, McGill, Janet B, Mechanick, Jeffrey I, Rosenblit, Paul D, Umpierrez, Guillermo E

Get more information

Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records by Xie, Yan, Bowe, Benjamin, Xian, Hong, Loux, Travis, McGill, Janet B, Al-Aly, Ziyad

“…Randomised clinical trials showed that compared with placebo, SGLT2 inhibitors and GLP-1 receptor agonists reduced risk of adverse cardiovascular events. The…”
Get full text

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes by Cooper, Mark E., MBBS, PhD, Perkovic, Vlado, MBBS, PhD, McGill, Janet B., MD, Groop, Per-Henrik, MD, DMSC, Wanner, Christoph, MD, Rosenstock, Julio, MD, Hehnke, Uwe, MSc, Woerle, Hans-Juergen, MD, von Eynatten, Maximilian, MD

“…Background Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2 diabetes,…”
Get full text

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) by Green, Jennifer B, Mottl, Amy K, Bakris, George, Heerspink, Hiddo J L, Mann, Johannes F E, McGill, Janet B, Nangaku, Masaomi, Rossing, Peter, Scott, Charlie, Gay, Alain, Agarwal, Rajiv

“…ABSTRACT Background Despite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and…”
Get full text

Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies by McGill, Janet B, Ahmann, Andrew

“…Continuous glucose monitoring (CGM) is developing into an increasingly useful tool for glucose monitoring and therapeutic guidance in the treatment of…”
Get more information

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study by McGill, Janet B, Sloan, Lance, Newman, Jennifer, Patel, Sanjay, Sauce, Christophe, von Eynatten, Maximilian, Woerle, Hans-Juergen

“…This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and…”
Get full text

Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events by Xie, Yan, Bowe, Benjamin, Gibson, Andrew K, McGill, Janet B, Yan, Yan, Maddukuri, Geetha, Al-Aly, Ziyad

“…To examine the comparative effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin and other non-SGLT2i antihyperglycemics on the…”
Get full text